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Abstract
Arbidol (ARB, also known as umifenovir) is used clinically in several countries as an anti-influenza virus drug. ARB inhibits 
multiple enveloped viruses in vitro and the primary mode of action is inhibition of virus entry and/or fusion of viral membranes 
with intracellular endosomal membranes. ARB is also an effective inhibitor of non-enveloped poliovirus types 1 and 3. In the 
current report, we evaluate the antiviral potential of ARB against another picornavirus, foot-and-mouth disease virus (FMDV), 
a member of the genus Aphthovirus and an important veterinary pathogen. ARB inhibits the replication of FMDV RNA sub-
genomic replicons. ARB inhibition of FMDV RNA replication is not a result of generalized inhibition of cellular uptake of cargo, 
such as transfected DNA, and ARB can be added to cells up to 3 h post-transfection of FMDV RNA replicons and still inhibit FMDV 
replication. ARB prevents the recovery of FMDV replication upon withdrawal of the replication inhibitor guanidine hydrochloride 
(GuHCl). Although restoration of FMDV replication is known to require de novo protein synthesis upon GuHCl removal, ARB does 
not suppress cellular translation or FMDV internal ribosome entry site (IRES)-driven translation. ARB also inhibits infection 
with the related Aphthovirus, equine rhinitis A virus (ERAV). Collectively, the data demonstrate that ARB can inhibit some non-
enveloped picornaviruses. The data are consistent with inhibition of picornavirus genome replication, possibly via the disrup-
tion of intracellular membranes on which replication complexes are located.
INTRODUCTION
The positive-sense RNA viruses of the family Picornaviridae 
include numerous important human and animal pathogens 
[1]. The family is divided into over 40 genera, including the 
genus Aphthovirus, which is composed of four species: bovine 
rhinitis A virus, bovine rhinitis B virus, equine rhinitis A virus 
and foot-and-mouth disease virus (FMDV) [1]. Whereas the 
first three of these species are of little medical or veterinary 
importance, FMDV is the causative agent of foot-and-mouth 
disease: a highly contagious, systemic infection of domestic 
and wild cloven-hooved ruminants [2]. The virus is endemic 
to many parts of the world, resulting in significant reductions 
in productive yields [3]. In disease-free countries, outbreaks 
in the population of domestic livestock result in the culling 
of millions of animals and significant economic losses. Major 
outbreaks in recent years have included the 2001 outbreak in 
the UK, which resulted in economic losses estimated at £8 
billion [4, 5]. Although vaccines are available, control of the 
disease is limited by several factors. These include multiple 
virus serotypes and subtypes, the difficulty in distinguishing 
vaccinated from infected animals and an asymptomatic 
carrier state that some animals can develop [5, 6].
Picornaviruses are single-strand, positive-sense RNA viruses, 
with genomes ranging in size from 7 to 9 kilobases. The 
viral genome lacks a 5′ methylguanosine cap but instead 
contains a virion protein (VPg) that is covalently linked to 
the genome. At both the 5′ and the 3′ ends of the genome, 
there are untranslated regions (UTRs). The 5′UTR serves 
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to initiate viral protein translation from a highly structured 
element called the internal ribosome entry site (IRES), while 
the 3′UTR plays a role in replication [1]. Between the 5′UTR 
and 3′UTR lies the coding region for the viral proteins that 
are expressed as a polyprotein. For FMDV, the order of viral 
proteins (encoded from 5′ to 3′) is Lpol protease, followed by P1 
viral capsid proteins 1A, 1B, 1C, 1D [1]. Encoded next are the 
P2 viral non-structural proteins 2A, 2B and 2C with functions 
in genome replication, followed by P3 proteins comprising 
3A, 3B1-3 and 3Cpro protease, and 3Dpol protein, which encodes 
the RNA-dependent RNA polymerase [1]. Individual viral 
proteins are generated by cleavage of the polyprotein by 
virally encoded proteases. All picornaviruses encode the viral 
protein 3Cpro, while FMDV encodes an additional protease, 
Lpro, which cleaves itself from VP4 at the 5′ end of the genome 
[1]. In this study, we used FMDV replicons where the P1 viral 
structural proteins 1A, 1B, 1C and 1D were replaced with a 
Ptilosarcus gurneyi (sea pansy) GFP (ptGFP) open reading 
frame (ORF). When transfected into mammalian cells, in 
vitro-transcribed RNAs from this construct are replication-
competent and produce high-level GFP expression, thereby 
facilitating studies on FMDV replication under Biological 
Safety Level 2 (BSL2) containment [7, 8].
The replication of most positive-sense RNA viruses occurs 
within, or on, cytoplasmic membrane-associated compart-
ments. In the case of picornaviruses, these compartments 
must contain viral non-structural proteins including the viral 
RNA-dependent RNA polymerase (3DPOL), and primer for 
replication (known as 3B), along with host cell factors [1]. 
In co-localizing these components, the compartments are 
thought to provide a favourable environment for the synthesis 
of new viral genomes from the template positive strand via 
a negative strand intermediate. Generation of these replica-
tion compartments or ‘factories’ requires the subversion of 
host cell membranes that are derived from several host cell 
organelles [9]. Preventing the formation of such complexes 
would be an attractive target for the development of anti-viral 
therapeutics with a potentially broad action.
Arbidol (ARB, also known as umifenovir; PubChem CID 
131410; Fig. 1), is a synthetic antiviral drug developed over 
30 years ago to combat seasonal influenza virus [10]. ARB has 
been shown to inhibit viruses from many different families, 
including Orthomyxoviridae [11], Paramyxoviridae [12], 
Bunyaviridae [13], Rhabdoviridae [14], Togaviridae [15], 
Hepadnaviridae [16], Hepaciviridae [10, 17–20], Filoviridae 
[21], Arenaviridae [21, 22] and Flaviviridae [23, 24]. While 
all of these are enveloped viruses, ARB also inhibits non-
enveloped viruses such as members of the Picornaviridae; 
specifically, poliovirus types 1 [25] and 3 (PV-1 and 3) [21]. 
In the current study, we evaluate the antiviral potential of 
ARB against FMDV, a picornavirus that causes widespread 
disease in animals.
RESULTS
FMDV sub-genomic replicons are a useful tool to study 
virus replication and antiviral efficacy under BSL2 contain-
ment. Replication can be assessed by the expression of a 
GFP reporter gene, by comparison to a replication-defective 
construct, which indicates the level of input translation. As a 
positive control, we used guanidine hydrochloride (GuHCl), 
a known inhibitor of picornavirus replication [26–29]. As 
expected, GuHCl abolished the replication of an FMDV 
replicon (P<0.001; Fig. 2). ARB (Fig. 1) treatment resulted in 
a dose-dependent suppression of FMDV replication, assessed 
as GFP fluorescence measured using an IncuCyte imaging 
system (Fig. 2, P<0.001). Doses of ARB of 9.4 µM and higher 
caused significant inhibition of FMDV replication (P=0.035 
and lower). Non-linear regression analysis suggested that 
the concentration of ARB that caused 50 % suppression of 
FMDV replication (IC50) ranged from 7 to 8.7 µM between 4 
to 10 h post-transfection. Although not achieving statistical 
significance (P=0.2), even the lowest dose of ARB tested 
(1.88 µM) caused visible reduction in GFP expression (i.e. 40– 
48 % inhibition, Fig. 2b).
While GuHCl is a potent inhibitor of picornavirus replica-
tion, the effect is reversible [26]. GuHCl also caused potent 
suppression of FMDV replication (P<0.0001), and removal 
of GuHCl at 4 h post-transfection of FMDV RNA led to 
a rapid recovery in FMDV replication (Fig. 3a, b). Since 
ARB has been shown to block an early step in the infection 
of cells by many viruses [10, 17–23, 30], we performed a 
time-of-addition experiment to define the latest time at 
which ARB could be added to replicon-transfected cells 
and still inhibit FMDV replication. Fig. 3c shows that ARB 
can be added up to 3 h post-transfection and still cause 
significant inhibition of FMDV replication. Although 
adding ARB at 4 h post-transfection caused inhibition 
of FMDV replication, the effect did not always achieve 
statistical significance (see below). We next examined the 
effect of ARB and GuHCl on FMDV replication, choosing 
4 h post-transfection as the time to compare the effect of 
ARB addition and GuHCl removal. As in Fig. 2, both ARB 
and GuHCl inhibited FMDV replication when added to 
cells just before transfection (Fig. 3d red and green bars, 
P<0.001). ARB inhibited replicon replication when added 
4 h post-transfection, albeit less efficiently (Fig. 3D, purple 
Fig. 1. Structure of arbidol (ARB).
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bars, P=0.015) as compared to when it was added at the 
start of the experiment. When GuHCl was removed at 
4 h post-transfection, FMDV replication was reactivated 
(Fig. 3d, orange bars, P<0.001). ARB, when added to cells 
from the start of the experiment, inhibited the resumption 
of FMDV replication when GuHCl was removed (Fig. 3d, 
black bars, P<0.001). Delaying the addition of ARB to cells 
until 4 h post-transfection also inhibited the resumption of 
FMDV replication upon GuHCl removal, but the inhibition 
was less effective as compared to when ARB was added to 
cells at the start of the experiment (data now shown). These 
data suggest that ARB is maximally effective in suppressing 
FMDV replication when added to cells before and within 
the first 3 h of transfection of FMDV RNA replicons, and 
that ARB can inhibit the recovery of FMDV replication 
upon GuHCl withdrawal. ARB had minimal effects on 
basal GFP levels expressed from replication-defective 
FMDV replicons that contained a mutation in the FMDV 
RNA polymerase active site (GNN; data not shown). The 
data suggest that ARB directly inhibits FMDV replication, 
does not affect transfection of the RNA replicon itself, 
and does not affect translation from input FMDV RNA 
templates (see below).
Because ARB did not significantly inhibit FMDV replication 
when added 4 h post-transfection of FMDV RNA replicons, 
and because ARB can block the entry of many enveloped 
viruses [10, 21–23], we asked whether ARB could inhibit 
the transfection that is required to initiate FMDV replicon 
replication. For this, we tested the ability of ARB to inhibit 
GFP expression following plasmid DNA transfection. When 
ARB was only incubated with cells during the 4 h transfec-
tion, there was no effect on GFP expression when analysed 
microscopically (Fig. 4b) or by Western blot (Fig. 4c, d). The 
data indicate that ARB does not affect the uptake of cargo 
such as plasmid DNA.
Resumption of picornavirus replication upon the removal 
of GuHCl requires de novo protein synthesis [29]. Since 
ARB inhibits the recovery of FMDV replication upon 
GuHCl withdrawal, we hypothesized that ARB might be 
inhibiting translation. More specifically, we posited that 
ARB inhibits FMDV translation, which is initiated in a cap-
independent fashion by an IRES, a feature in the 5′ UTRs 
of many positive-strand RNA viruses, including FMDV 
[31, 32]. To test the hypothesis, we utilized a plasmid, 
pRF-FMDV, which produces a bicistronic RNA containing 
two ORFs for two different luciferase reporters. The first 
ORF expresses Renilla luciferase by cellular cap-dependent 
translation (and can also initiate translation from non-
capped RNAs [33]), while the second ORF expresses 
firefly luciferase from the FMDV IRES (Fig. 5a) [34, 35]. 
When the pRF-FMDV plasmid DNA was transfected into 
Huh7.5.1 cells, the translation inhibitor cycloheximide 
(CHX) suppressed both Renilla and firefly luciferase levels, 
indicating suppression of translation (Fig. 5b). Removal of 
CHX relieved the suppression of translation, resulting in 
strong induction of translation from both reporters, and 
Fig. 2. ARB inhibits FMDV replication. BHK-21 cells treated with DMSO, 2 mM guanidine hydrochloride (GuHCl), or the indicated doses of 
ARB were immediately transfected with wild-type GFP FMDV replicon. (a) FMDV replication was monitored by total GFP expression at 
hourly intervals over 10 h. Absolute values for total GFP intensity per well from a representative experiment of two independent repeats 
are shown. The data depict the means and standard deviations of duplicate measurements for each condition. (b) Representative images 
of total cells and GFP-positive cells from the 8 h timepoint.
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ARB treatment had minimal effects on translation from 
both reporters (Fig. 5b). To reinforce these data, we gener-
ated bicistronic RNA from the pRF-FMDV plasmid by 
in vitro transcription. We did not add 5′ methylguanosine 
caps to these RNA transcripts, as we have previously shown 
that non-capped RNAs are efficiently translated [33], 
presumably due to the high level of RNA in the cytoplasm 
following transfection, which leads to translational initia-
tion by ribosome scanning, as previously demonstrated 
for non-capped mRNAs [36]. As expected, CHX treatment 
reduced the expression of both Renilla and firefly lucif-
erases (Fig. 5c). Although ARB showed some reduction of 
FMDV-IRES-driven firefly luciferase, ARB caused a more 
pronounced, dose-dependent suppression of cell viability 
(Fig. 5c). Taken together, these data indicate that ARB does 
not suppress translation.
Due to stringent regulations that restrict work with infectious 
FMDV, it was not possible to extrapolate our FMDV replicon 
data to determine the effect of ARB on FMDV infection. As an 
alternative approach to validate the FMDV replicon data we 
therefore tested ARB against equine rhinitis A virus (ERAV), 
a picornavirus in the same genus as FMDV (Aphthovirus). 
Unlike FMDV, ERAV can be propagated in a standard BSL2 
containment laboratory. ARB was added to overlay media 
in both plaque and TCID50 ERAV titration assays after a 
Fig. 3. ARB inhibits recovery of FMDV replication after GuHCl withdrawal. (a) GuHCl reversibly inhibits FMDV replication. BHK-21 cells 
were transfected with wild-type GFP FMDV replicon and immediately treated with DMSO or DMSO plus 2 mM GuHCl. GuHCl was either 
left on for the duration of the experiment (GuHCl left on) or removed at 4 h post-transfection (p.t.; GuHCl removed 4 h p.t.) and replaced 
with normal media. FMDV replication was monitored by total GFP expression at hourly intervals over 17 h. The data are representative 
of an experiment that was performed five times: pooled data from the five replicates are shown in (b), where P values were derived from 
one-tailed t-tests in Excel, with the comparison groups connected via the indicated lines. (c) BHK-21 cells were treated at the indicated 
times with 10 μM ARB (or ethanol solvent control, EtOH) in the context of transfection with the FMDV RNA that expresses HA-tagged 
3A and Flag-tagged 3D proteins. FMDV replication was monitored by total GFP expression at hourly intervals over 14 h. The data are 
derived from a single experiment. (d) BHK-21 cells were transfected with the FMDV replicon containing HA-tagged 3A and Flag-tagged 
3D RNA replicon. Just prior to addition of transfection complexes, media containing the following compounds were added to separate 
wells of cells: 0.1 % ethanol (EtOH, blue bars), 10 μM ARB (ARB, red bars), 2 mM GuHCl (green bars). Separately, ARB was added 4 h 
post-transfection (ARB @4 h, purple bars). GuHCl was also removed at 4 h post-transfection (GuHCl off @4 h) and replaced with media 
containing 0.1 % ethanol (EtOH, orange bars) or 10 μM ARB (black bars). In the GuHCl removal arm, both EtOH and ARB were added with 
GuHCl at the start of the experiment. FMDV replication was monitored by total GFP expression at hourly intervals over 12 h. The data 
depict the means and standard deviations of three separate experiments, with all conditions in triplicate. P values for panels (c) and (d) 
were derived from one-way ANOVA tests in GraphPad Prism, with the comparison groups connected via the indicated lines.
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1 h adsorption of virus to cells. Fig. 6 shows that ARB caused 
dose-dependent inhibition of ERAV in both titration assays 
with an IC50 of approximately 4–5 µM.
DISCUSSION
In addition to the clear antiviral effects of ARB that suppress the 
entry of enveloped viruses, specifically fusion [10, 17–22, 30], 
ARB also inhibits the infection of cells by non-enveloped 
picornaviruses, including PV-1 [25] and PV-3 [21] while, as 
shown in this report, it inhibits FMDV replication and ERAV 
infection. We know that ARB can inhibit enveloped viruses 
by blocking post-entry events because of studies showing that 
ARB inhibits non-infectious HCV replicons [18], while the 
drug can inhibit Ebola virus and Zika virus when added up 
to 24 h post-infection [21, 23]. Although the ability of ARB 
to suppress virus replication when added after infection is not 
as great compared to when cells are treated with ARB before 
or within a few hours of infection, collectively these studies 
indicate that ARB inhibits virus replication.
A major question for future work is how ARB blocks FMDV 
replication and how it prevents the resumption of FMDV 
replication upon GuHCl removal. ARB is known to engage 
membranes [19, 20], so this activity should be considered as 
a potential mechanism for the suppression of FMDV repli-
cation. This indole-based hydrophobic molecule displays 
dual binding capacity to both lipid membrane interfaces 
and to aromatic protein residues and viral proteins that are 
embedded in membranes [20, 30]. Thus, ARB might also 
impair virus replication on intracellular membranes which 
are remodelled during the replication of many positive-strand 
viruses, including picornaviruses [9, 37]. Previous studies 
with GuHCl to stall poliovirus replication showed that GuHCl 
does not inhibit the synthesis or processing of viral proteins 
[27], yet de novo protein synthesis and cellular factors are 
required to resume replication upon GuHCl removal [27, 29]. 
Moreover, GuHCl blocks negative-strand synthesis in cell-
free systems [28], possibly through inhibition of the viral 
2C protein, which is a membrane-associated component of 
the viral RNA replication complex [38, 39]. Indeed, GuHCl-
resistant mutants map to the 2C protein for several picorna-
viruses, including FMDV [29, 40]. Since ARB did not inhibit 
translation, we can rule out inhibition of de novo protein 
synthesis as the mechanism of action for ARB suppression 
of resumption of FMDV replication upon GuHCl removal. 
Instead, ARB showed maximal inhibition of FMDV replica-
tion when cells were treated 1 h before, and up to 3 h after, the 
transfection of FMDV RNA replicons. If ARB requires time 
to impregnate intracellular membranes, then it might disrupt 
the interactions of nascent viral replication complex proteins 
with membranes. Disruption of protein–protein interactions 
during replication complex formation is also possible, given 
the propensity of ARB to engage membranes, proteins in 
membranes and protein conformational changes [20, 30]. 
However, since ARB can still suppress FMDV replication 
when added up to 3 h post-transfection of FMDV RNA repli-
cons, and ARB does not inhibit cellular or IRES-mediated 
translation, it is not likely to inhibit early replication events, 
such as polyprotein expression and proteolytic processing. The 
fact that ARB can be added up to 3 h post-infection suggests 
that it is also not inhibiting either positive- or negative-strand 
RNA synthesis, as both of these processes occur within the 
first 3 h of picornavirus infection [41]. Furthermore, during 
poliovirus infection, the intracellular location of viral proteins 
and positive- and negative-strand RNA changes over time. 
Within the first 2.5 h of infection, input positive-strand RNA 
and the viral 2B protein are translated on the endoplasmic 
reticulum, producing a diffuse cytoplasmic staining pattern, 
which correlates with the formation of virus-induced intra-
cellular vesicles [41], a hallmark of intracellular membrane 
rearrangement associated with poliovirus infection [42]. By 
3.5 h of infection, viral RNAs, the 2B protein and vesicles 
move closer to the nucleus, generating a punctate perinu-
clear staining pattern [41]. This movement is dependent 
on microtubules, since the migration can be inhibited with 
nocodazole [41]. Moreover, GuHCl causes viral 2B protein 
and positive-strand RNA to become concentrated as large 
juxtanuclear dots associated with the Golgi apparatus [41]. 
Fig. 4. ARB does not block uptake of plasmid DNA. (a) Schematic of 
experiment. Huh7.5.1 cells were transfected with pEGFP plasmid using 
X-tremeGENE 9 DNA Transfection Reagent. Cells were incubated with 
DNA–transfection cocktail for 4 h in the presence of ethanol solvent 
control (EtOH) or 18.8 μM of ARB in ethanol. The inocula were removed, 
the cells were washed and fresh medium (without EtOH or ARB) was 
added to the cells. GFP was measured at 24 h post-transfection. 
(b) Representative EVOSfl microscopy images of EtOH- versus ARB-
treated cells. (c) Representative Western blot of GFP and vinculin 
(a cellular protein control) in EtOH- versus ARB-treated cells. (d) Band 
intensity analysis of the cells that were treated with EtOH or ARB for 
4 h during transfection. The data are derived from three independent 
experiments and represent the averages and standard deviations of 
GFP pixel intensities normalized to cellular vinculin levels.
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Fig. 5. ARB does not inhibit translation. (a) Schematic of bicistronic reporter gene plasmid, pRF-FMDV, showing the translation of Renilla 
luciferase (R-luc) regulated by standard cellular translation, whereas firefly luciferase (F-luc) is translated from the FMDV internal 
ribosome entry site (IRES). (b) pRF-FMDV plasmid DNA was transfected into Huh7.5.1 hepatoma cells and 18 h later cells were treated 
with DMSO or 10 μg ml−1 cycloheximide (CHX) for 6 h. CHX-treated cells were then washed and medium containing ethanol solvent control 
(EtOH) or the indicated doses of ARB solubilized in EtOH was added to cells. Renilla and firefly luciferase activity was measured 24 h later 
by DualGlo assay. Viability was measured in parallel wells by measuring ATP levels via ATPlite assay. The data shown are normalized 
to the 6 h DMSO control and represent the means and standard deviations of triplicate samples per condition. The experiment was 
performed once. (c) Ethanol (EtOH), the indicated doses of ARB solubilized in EtOH, or CHX was added to Huh7 cells immediately before 
lipofectin-based transfection of 50 ng of in vitro-transcribed RNA from pRF-FMDV. Renilla and firefly luciferase activity was measured 
17 h later by DualGlo assay. Cell viability was measured via ATPlite assay. The experiment was performed twice and the data represent 
pooled data with each condition in each experiment performed in triplicate.
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Within 1 h of GuHCl removal, positive-strand RNA and 2B 
protein move from the large juxtanuclear dots back to the 
diffuse cytoplasmic ER staining pattern, and after 1.5 h of 
GuHCl release, positive- and negative-strand RNA and viral 
2B protein re-establish their punctate perinuclear staining 
[41]. Thus, it is possible that the propensity of ARB to interact 
with proteins embedded in membranes and membranes 
themselves could influence the trafficking and/or integrity of 
replication complexes on intracellular membranes that are 
required to resume FMDV replication upon GuHCl removal. 
These hypotheses merit further study.
ARB has been used clinically for decades in several coun-
tries, with minimal side-effects and a good pharmacoki-
netic profile [10, 17, 43]. Further studies on ARB in the 
context of FMDV infection, replication and in small animal 
models are required to determine whether ARB has utility 
for prophylactic and therapeutic use in FMD outbreaks in 
animals.
METHODS
Starting material
ARB (Fig. 1) was synthesized commercially. Purity and struc-
ture were confirmed as described [21]. ARB was dissolved in 
ethanol or DMSO.
Cells
Huh7.5.1 (human hepatoma [44]), Huh7 (human hepatoma 
[45]), Vero (African green monkey kidney [46]), adherent 
HeLa Ohio (human epithelial carcinoma cells) and BHK-21 
(baby hamster kidney cells) cells [47] were grown as described 
previously [48, 49].
FMDV replicons
The FMDV replicon plasmids, pRep-ptGFP, and the equiva-
lent constructs containing the replication-defective 3Dpol-
GNN point mutation to the RNA polymerase have already 
been described [8]. For some experiments, a GFP-expressing 
replicon construct containing HA-tagged 3A and Flag-tagged 
3D proteins was also used. The insertion of either epitope 
tag does not affect replicon replication, as we have previously 
described [8, 50]. Replicon plasmid was linearized with AscI 
(NEB) before use in T7 in vitro transcription reactions as 
previously described [8]. Replicon RNA was purified using 
an RNA Clean and Concentrator-25 kit (Zymo Research), 
following the manufacturer’s instructions. Prior to transfec-
tion, transcripts were quantified and qualified by denaturing 
MOPS/formaldehyde gel following standard protocols.
Viruses
Viral stocks of equine rhinitis A virus (ERAV) [51] were 
generated by infecting HeLa Ohio cells at a multiplicity 
Fig. 6. ARB inhibits ERAV infection. (a) BHK-21 cells were infected with serial 1 : 10 dilutions of ERAV virus stock for 1 h at 37 ˚C. Virus 
inocula were removed and cells were overlaid with overlay media containing the indicated doses of ARB. Plaques were stained with 
crystal violet 96 h post-infection. Plaques were counted and titres were calculated as described in the Methods section. (b) BHK-21 
cells were infected with serial 1 : 10 dilutions of ERAV virus stock for 1 h at 37 ˚C. Virus inocula were removed and cells were overlaid 
with fresh media containing the indicated μM doses of ARB. Cells were stained with crystal violet 72 h later. The TCID
50
 was calculated 
as described in the the Methods section. (c) Representative titre plates from the data shown in (a) (−2 and −3 refer to serial 1 : 100 and  
1 : 1000 dilutions of ERAV-containing supernatants). The plaque assay and TCID
50
 assay were each performed once.
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of infection (m.o.i.) of 1. The resulting supernatants were 
harvested by low-speed centrifugation and titred on HeLa 
Ohio cells by standard plaque assay [52].
ARB treatment
ARB was added to cells before virus infection or FMDV RNA 
replicon transfection, except for in time-of-addition studies, 
where the drug was added before, during and after infection 
or transfection. Please refer to the figure legends for details 
of when ARB was added.
FMDV replication assay
BHK-21 cells seeded into 24-well tissue culture plates were 
allowed to adhere for 16 h before replicate wells were trans-
fected with replicon transcripts at 500 ng RNA per well 
using Lipofectin reagent (Thermo Scientific) as previously 
described [49]. Arbidol was added directly to duplicate wells 
per concentration assayed at the indicated time points rela-
tive to transfection. Fluorescent reporter protein expression 
was monitored using an IncuCyte Zoom Dual Color FLR 
(Essen BioSciences) within a 37 °C humidified incubator. 
Wells were scanned hourly up to 24 h post-transfection and 
captured images were analysed using the associated software 
for fluorescent protein expression. The fluorescent thresholds 
for analysis were determined using control transfections and 
were used to identify fluorescent positive objects from back-
ground fluorescence, as described previously [49].
ERAV infection
The titres of ERAV were determined by plaque assay following 
standard procedures. Briefly, serial dilutions of virus or 
virus complexes were added to HeLa Ohio cell monolayers 
and incubated on a rocking platform for 60 min. The virus 
inoculum was removed and replaced by growth medium 
containing 1 % agarose (Lonza SeaKem LE) supplemented 
with arbidol at the indicated concentration. The plates were 
incubated for 96 h and fixed with 4 % paraformaldehyde, and 
plaques were visualized by crystal violet staining. For TCID50 
determinations, 96-well plates were seeded with 1×104 Vero 
cells per well in 100 µl of complete growth media and grown 
overnight. ERAV was serially diluted 1 : 10 from 10−1 to 10−7 
in serum-free medium and 100 µl of each dilution was added 
to cells in triplicate. Serum-free medium alone was added 
as a negative control. Virus was adsorbed to cells for 2 h at 
37 ˚C, after which it was removed and replaced with 
100 µl of medium containing various concentrations of ARB. 
Cells were fixed in 4 % paraformaldehyde for 20 min before 
being stained with crystal violet. The TCID50 was calcu-
lated using Reed–Muench method, using a freely available 
calculator [53].
Plasmid uptake assay
Huh7.5.1 cells were seeded in 12-well tissue culture plates 
at 200 000 cells per well. The next day, cells were transfected 
with 500 ng/well of pEGFPN1 plasmid (Clontech) using 
X-tremeGENE 9 DNA Transfection Reagent (Sigma Aldrich). 
Cells were incubated with DNA transfection cocktail for 4 h 
in the presence of ethanol solvent control (EtOH) or 18.8 µM 
of ARB in ethanol. The medium and drugs were removed, the 
cells were washed and fresh medium without drugs was added 
to the cells. GFP was measured at 24 h post-transfection, 
both by Western blot with anti-GFP antibodies (sc-9996, 
Santa Cruz Biotechnology) and by EVOS-FL fluorescence 
microscopy (Thermo Fisher). Western blots were imaged 
by the Odyssey imaging system (LI-COR). GFP levels were 
normalized against Western blot detection of the cellular 
protein vinculin (sc-73614, Santa Cruz Biotechnology). For 
all Western blots, Image Studio (LI-COR) software was used 
to obtain Western blot images, using the default instrument 
settings of resolution at 169 µm and scan quality set to lowest. 
Any image manipulations were manually applied equally 
across the entire image and were applied equally to controls. 
The manipulations consisted of adjusting the brightness and 
contrast and/or flipping the image to obtain the proper orien-
tation. Using Image Studio software, rectangles of identical 
size and area were drawn around GFP and vinculin to obtain 
pixel intensities, which were exported into Excel. GFP levels 
were normalized to vinculin levels. ARB-treated samples were 
then normalized to the EtOH by dividing the normalized 
GFP intensity of ARB-treated cells by the normalized GFP 
intensity of ethanol-treated cells.
Translation assays
Bicistronic plasmid DNA was obtained from Kensuke 
Hirasawa (Memorial University). The plasmid contains 
two luciferase reporter genes: Renilla luciferase (R-luc) 
whose translation is 5′ methylguanosine cap-dependent, 
and firefly luciferase (F-luc), which is translated by an 
FMDV IRES [34]. Fifty nanograms of the bicistronic 
plasmid DNA was transfected into Huh7.5.1 hepatoma cells 
using X-tremeGENE 9 DNA Transfection Reagent (Sigma 
Aldrich), and 18 h later the cells were treated with DMSO 
or 10 µg ml−1 cycloheximide (CHX) for 6 h. CHX-treated 
cells were then washed and medium containing EtOH or 
the indicated doses of ARB solubilized in EtOH was added 
to the cells. Renilla and firefly luciferase activity was meas-
ured 24 h later by DualGlo assay (Promega). Viability was 
measured in parallel wells by measuring the ATP levels via 
ATPlite assay (Perkin Elmer).
In vitro transcription of bicistronic constructs
RNA was also generated from the pRF-FMDV plasmids using 
the RiboMax kit (Promega). Plasmids were linearized with 
BamHI and run-off transcripts were made. For this study, we 
did not cap RNA transcripts from these plasmids, as we have 
previously shown that non-capped RNAs are translated [33] 
because of the high level of RNA in the cytoplasm following 
transfection, which leads to translational initiation by ribo-
some scanning [36]. Huh7 cells were treated with EtOH, ARB 
solubilized in EtOH, or with CHX immediately before 50 ng 
of RNA was transfected into Huh7 cells using Lipofectin 
(Invitrogen). Renilla and firefly luciferase activity was meas-
ured 17 h later by DualGlo assay (Promega).
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Cytotoxicity testing
The cytotoxicity of ARB on Huh7.5.1 or Huh7 cells was evalu-
ated by measuring cellular ATP levels with a commercial kit 
(ATPlite assay, Perkin Elmer) or by MTT assay. The cytotox-
icity of ARB on BHK-21 cells was measured using MTS assay 
(Promega).
Statistics
Data were analysed by one-sided t-tests in Excel software or 
by one-way analysis of variance (ANOVA) using GraphPad 
Prism software.
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